REG - Oncimmune Hldgs PLC - ImmunoINSIGHTS and Synexa partnership

Oncimmune HoldingsAnnouncement

01/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220301:nRSA1123Da&default-theme=true

RNS Number : 1123D  Oncimmune Holdings PLC  01 March 2022

1 March 2022

 

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

ImmunoINSIGHTS and Synexa Life Sciences sign go-to-market service partnership

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics
group, is pleased to announce the signing of a go-to-market partnership with
Synexa Life Sciences BV, a global leader in biomarker and bioanalytical
science, focused on delivering a range of biomarker analytical and advisory
services in translational and clinical research.

 

Following an assessment of ImmunoINSIGHT's competence and capability, Synexa
Life Sciences has selected Oncimmune's ImmunoINSIGHTS platform to provide its
clients access to specialist autoantibody services. This collaborative
partnership will allow for comprehensive characterisation of the B-cell immune
response in a wide range of disease and treatment indications.

 

Both companies utilise technologies to identify biological signatures,
leveraging their deep expertise in the immunological underpinnings of health
and disease to improve patient diagnostics and therapeutics. Over the next 18
months, Synexa Life Sciences plans to sign multiple new contracts with their
partners for autoantibody profiling acting to broaden and enhance
ImmunoINSIGHT's own business development efforts.

 

This new strategic collaboration comes at a time when autoantibody profiling,
which provides a depth and breadth of clinical data to improve response and
adverse event (irAE) prediction, patient screening and diagnostic accuracy, is
experiencing substantial interest, with the market segment growing at
approximately 27% year-upon-year.

 

Dr Adam M Hill, CEO of Oncimmune said: "We welcome this exciting initiative
with Synexa Life Sciences, who have recognised the recent progress made by our
ImmunoINSIGHTS platform. The ImmunoINSIGHTS team look forward to the
opportunity to deliver high quality, value-adding analysis and interpretation
of blood samples for Synexa and its clients, delivering a differentiated
service to customers that are yet to engage with our proprietary technology
platform."

 

For further information:

 

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

contact@oncimmune.co.uk (mailto:contact@oncimmune.co.uk)

 

Singer Capital Markets (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

 

WG Partners (Joint Broker)

David Wilson, Nigel Barnes, Erland Sternby

+44 (0)20 3705 9321

 

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com (mailto:Oncimmune@fticonsulting.com)

+44 (0)20 3727 1000

 

About Oncimmune

 

ImmunoINSIGHTS Service Business

 

Oncimmune is a leading immunodiagnostics developer, primarily focused on the
growing fields of immuno-oncology, autoimmune disease and infectious diseases.
The ImmunoINSIGHTS service business leverages Oncimmune's technology platform
and methodologies across multiple diseases, to offer life-science
organisations actionable insights for therapies across the development and
product lifecycle. Our core immune-profiling technology is underpinned by our
library of over eight thousand immunogenic proteins, one of the largest of its
kind. This helps identify trial participants and patients into clinically
relevant subgroups, enabling development of targeted and more effective
treatments.

 

Oncimmune's ImmunoINSIGHTS service business is based at the Company's
discovery research centre in Dortmund, Germany. The business platform enables
life science organisations to optimise drug development and delivery, leading
to more effectively targeted and safer treatments for patients.

 

The ImmunoINSIGHTS development team is based in the US and Europe and
Oncimmune is seeking to replicate the Dortmund facility in the US in the
medium term.

 

EarlyCDT Product Business

 

Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help
identify cancer on average four years earlier than standard clinical
diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market
estimated to grow to £3.8bn by 2024. With over 200,000 tests already
performed for patients worldwide and its use being supported by peer reviewed
data in over 12,000 patients, we are poised to become an integral component of
future lung cancer detection programmes, globally.

 

Oncimmune's diagnostic products business is located at its laboratory facility
in Nottingham, UK.

 

For more information, visit www.oncimmune.com (http://www.oncimmune.com)

 

About Synexa Life Sciences

 

For nearly 20 years, Synexa Life Sciences has supported their Biopharma
partners across the globe to achieve their clinical milestones. Founded in
2003 as an early pioneer in the biomarker field, Synexa specializes in the
development, validation and delivery of a wide range of complex and
custom-designed assays, founded on deep expertise in immunology and the impact
of the immune system on human health and candidate drug performance. For more
information, please visit www.synexagroup.com

 

Synexa is a privately-held company, backed by Gilde Healthcare, a specialized
European healthcare investor, and operates from three laboratory locations
(London, Berlin and Cape Town).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDGGDDXGDDGDI